Phase 1/2Completed
Phase 1b/2a Unblinded Study of Responses in Premenopausal Women With HSDD to Lorexys Evaluating Efficacy and Safety (PURPLE)
A Phase 1-b Non-blinded Study of Safety, Tolerability and Efficacy of Lorexys in Premenopausal Women With Hypoactive Sexual Desire Disorder
- Sponsor
- S1 Biopharma, Inc. (Industry)
- Enrolment
- 30 enrolled
- Conditions
- Hypoactive Sexual Desire Disorder (DSM-IV-TR Defined); Sexual Interest/Arousal Disorder (DSM-5 Defined)
- Interventions
- bupropion, Lorexys low-dose, Lorexys moderate-dose
- Ages
- adults
- Registry
- NCT01857596
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to investigate whether Lorexys is effective and safe to treat premenopausal women who have lost their sexual desire to a distressing degree.
Primary outcomes
- Change in Desire domain of the Female Sexual Function Index
History
Last registry update
Primary completion
Registered
Started